To the Editor In their Editorial about off-label use of gabapentin, Drs Wallach and Ross1 recommended several regulatory and postmarketing surveillance initiatives that could result in better efforts to evaluate the off-label safety and efficacy of medical products. The authors noted that with the exception of 2 indications approved by the US Food and Drug Administration (FDA) and 2 unapproved indications for gabapentin use, approximately 50 Cochrane reviews and updates of off-label use of gabapentin concluded there was “insufficient evidence, no benefit, or benefit based on low-quality evidence” for the off-label indications.